作者首先在拟南芥中应用TOP1抑制剂（TOP1i, TOP1 inhibitor）建立了一个反映R-loop水平与基因组拓扑状态的监测系统，发现CPT处理可显著促进根尖组织中基因组R-loop（拓扑结构发生改变导致的R-loop变化，简称为topoR-loop）水平和DNA断裂标记γH2AX水平的升高，并最终抑制根生长。利用CPT进行反向遗传筛选发现DNA损伤修复...
关键字:Top1 inhibitor 1|TargetMol 公司简介 TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及...
Top1 inhibitor 1 is a potent inhibitor of human topoisomerase I (Top1)(IC50: 29 nM). 规格价格库存数量 25 mg ¥ 10,600 6-8周 50 mg ¥ 13,800 6-8周 100 mg ¥ 17,500 6-8周 大包装 & 定制 加入购物车 TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们...
ASAP1, and MUC18, among others. MUC18 was overexpressed in both tumor cells and tumor-infiltrating blood vessels across major melanoma subtypes, making it a potential dual-compartment and universal melanoma therapeutic target. AMT-253, an MUC18-directed ADC based on topoisomerase I inhibitor exatec...
thus enabling selective destruction of cancer cells while minimizing systemic toxicity. DXd is a topoisomerase I inhibitor that induces DNA damage leading to cell cycle arrest, making it an option for ADC payloads. The DXd-ADC technology, developed by Daiichi Sankyo, is a cutting-edge platform th...
[1] Lin FT, Liu K, Garan LAW, et al. A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors.Proc Natl Acad Sci U S A.2023, 120(44): e2307793120. [2] Chowdhury P, Lin GE, Liu K, Song Y, Lin FT, Lin WC. Targeting TopBP1 at a conve...
2024 年 2 月 20 日,上海市卫生健康委员会消化系统肿瘤全程监测与精准干预重点实验室(SMHC)/复旦大学附属闵行医院的研究团队在 Cell Reports Medicine(IF14.3)期刊发表了题为:Disruption of MerTK increases the efficacy of checkpoint i...
Processing of TOP1cc may be an alternative, less frequent source of 2–5 bp deletions41, but we did not detect ID4 in cancers treated with topoisomerase 1 inhibitor (Extended Data Fig. 8j). The canonical function of TOP1 is to relieve DNA topological stress, arising during both ...
11月11日,来自美国癌症研究所和IQVIA的几位研究者在Nature Reviews Drug Discovery杂志上发表了题为“Combinations take centre stage in PD1/PDL1 inhibitor clinical trials”的分析报告,总结了目前PD-1/PD-L1抗体临床试验的现状以及患者招募方面所面临的挑战。
(FGF)-1 promotes proliferation and differentiation of human preadipocytes and recently demonstrated that bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) is a central, proximal effector. Herein, we describe the identification and characterization of carboxypeptidase X (CPX)-1, a ...